Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction.

ABSTRACT: The introduction of multiple new pharmacological agents over the past three decades in the field of heart failure with reduced ejection fraction (HFrEF) has led to reduced rates of mortality and hospitalizations, and consequently the prevalence of HFrEF has increased, and up to 10% of patients progress to more advanced stages, characterized by high rates of mortality, hospitalizations, and poor quality of life. Advanced HFrEF patients often show persistent or progressive signs of severe HF symptoms corresponding to New York Heart Association class III or IV despite being on optimal medical, surgical, and device therapies. However, a subpopulation of patients with advanced HF, those with the most advanced stages of disease, were often insufficiently represented in the major trials demonstra

SUBMITTER: Vishram-Nielsen JKK 

PROVIDER: S-EPMC8820365 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature